Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation

Europace

Volumn 18, Issue 8, 2016, Pages 1150-1157

  Beyer Westendorf, Jan ^a   Ehlken, Birgit ^b   Evers, Thomas ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b IQVIA   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

Dabigatran; Oral anticoagulation; Primary care; Real world; Rivaroxaban; Vitamin K antagonist

Indexed keywords

ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; DABIGATRAN; PHENPROCOUMON; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; VITAMIN K GROUP;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG USE; DYSPEPSIA; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; RISK REDUCTION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; CLINICAL TRIAL; COMPLICATION; FACTUAL DATABASE; GERMANY; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BLOOD COAGULATION; DABIGATRAN; DATABASES, FACTUAL; FACTOR XA INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR; RIVAROXABAN; STROKE; VITAMIN K;

EID: 84982102721     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv421     Document Type: Article

References (21)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 857-67
2. Ezekowitz MD, Spahr J, Ghosh P, Corelli K. Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. J Interv Card Electrophysiol 2014;40:261-8
3. Nelson WW, Song X, Coleman CI, Thomson E, Smith DM, Damaraju CV et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2014;30:2461-9
4. Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74
5. Laliberté F, Cloutier M, NelsonWW, Coleman CI, Pilon D, Olson WH et al. Realworld comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-25
6. Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the "disease analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 2009;47:617-26
7. Nelson WW, Song X, Thomson E, Smith DM, Coleman CI, Damaraju CV et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2015;31:1831-40
8. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidencebased pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-86
9. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015;13:495-504
10. Vrijens B, Urquhart J, White D. Electronically monitored dosing histories can be used to develop a medication-taking habit and manage patient adherence. Expert Rev Clin Pharmacol 2014;7:633-44
11. Witt DM. Approaches to optimal dosing of vitamin K antagonists. Semin Thromb Hemost 2012;38:667-72
12. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
13. Bakhai A, Sandberg A, Mittendorf T, GreinerW, Oberdiek AM, Berto P et al. Patient perspective on the management of atrial fibrillation in five European countries. BMC Cardiovasc Disord 2013;13:108
14. Beyer-Westendorf J, Fo rster K, Ebertz F, Gelbricht V, Schreier T, Go belt M et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015;17:530-8
15. Ho MH, Ho CW, Cheung E, Chan PH, Hai JJ, Chan KH et al. Continuation of dabigatran therapy in "real-world" practice in Hong Kong. PLoS One 2014;9:e101245
16. Beyer-Westendorf J, Ebertz F, Fo rster K, Gelbricht V, Michalski F, Kohler C et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC registry. Thromb Haemost 2015;113: 1247-57
17. Laliberté F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient 2013;6:213-24
18. Martinez C, Katholing A, Wallenhorst C, Freedman SB. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2015;114: doi:10.1160/TH15-04-0350
19. Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 2010;25:284-90
20. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S et al. XANTUS: a realworld, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2015; doi: 10.1093/eurheartj/ ehv466
21. Gadkari AS, McHorney CA. Medication nonfulfillment rates and reasons: narrative systematic review. Curr Med Res Opin 2010;26:683-705